Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 13.9% of the patients who received trastuzumab deruxtecan (grade 1 or 2 in 33 patients and grade 3 in 1) and in 1.3% ...

Both trastuzumab deruxtecan-nxki (Enhertu ... Interstitial lung disease and pneumonitis occurred more frequently in the T-DXd arm (13.9% vs. 1.3%), but only one participant had a grade 3 event ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and ...

The DESTINY-Breast11 study is pitting Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) against standard care – chemotherapy followed by THP as a pre ...

Datroway is the second ADC brought to market by AZ and Daiichi Sankyo after Enhertu (trastuzumab deruxtecan), an HER2-targeting ADC that brought in sales of more than $2.7 billion in the first ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

DATROWAY ® (datopotamab deruxtecan) has been approved in the ... occurred in 0.7% of patients due to interstitial lung disease/pneumonitis, dyspnea and sepsis. About TROPION-Breast01 TROPION ...